Light chain multiple myeloma revealed by a dorsal epidural compressive tumor.
[Light chain multiple myeloma revealed by a dorsal epidural compressive tumor]. Presse Med. 2018 Jan 17;: Authors: Turki M, Hdiji O, Farhat N, Haj Kacem H, Dammak M, Mhiri C PMID: 29373280 [PubMed - as supplied by publisher]
Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Eli Muchtar, Grace Lin, Martha GroganAbstractLight chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most commonly involved organ and the leading determinant of short and long-term survival. Pathogenic free light chains, fragments of intact immunoglobulins, are the amyloidogenic protein and are secreted by clonal bone marrow plasma cells. The goal of therapy is to cut-off the supply of these pathogenic light chains to allow organ r...
ConclusionsThe findings of this study support the usefulness of PET/CT in the detection of subcutaneous MZL, and in staging and treatment decisions.
Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractTo investigate the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib treatment strategy after first-line imatinib. We went through retrospective analysis of the efficacy and safety of imatinib versus nilotinib for first-line for CML-CP patients, and comparative analysis of the efficacy of sustained imatinib versus switchin...
A new triplet regimen -- carfilzomib, dexamethasone, and daratumumab -- has shown good results in patients with relapsed or refractory multiple myeloma.Medscape Medical News
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
· Updated data from the Phase 3 ALCYONE study showed an overall survival benefit and continued improvement in progression-free survival after a median duration of follow-up of more than three years with DARZALEX®; results simultaneously published in The Lancet· DARZALEX® is the only CD38-directe d antibody to show an overall survival benefit in multiple myeloma· Additionally, follow-up data from the Phase 3 MAIA study showed significant progression-free survival benefit continuing for three years following DARZALEX® treatment
Condition: Multiple Myeloma Intervention: Device: Free light chains Sponsor: University of California, San Francisco Recruiting
Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577)